Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-408-5 | CAS number: 103429-90-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: Evaluation of toxicokinietcs based on available data
- Adequacy of study:
- key study
- Study period:
- NA
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
Data source
Materials and methods
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Oral:
According to the ECHA Guidance Chapter R.7c (2017), molecules with molecular weights of less than 500 g/mol are small enough to be candidates for absorption by passive diffusion from the gastrointestinal tract. The molecular weight of MMB-AC is 160.21 g/mol, it is water soluble (58.3 g/L) and has an octanol-water partition coefficient (log Kow) of 1.6. This combination of aqueous and lipid solubility favors absorption by the oral route. Based on the hydrolysis data for MMB-AC, the substance is expected to be hydrolytically stable (pH-stable) in the small intestine and stomach.
The hypothesis for oral absorption is substantiated by observed negative effects (mortality, clinical signs) in the acute toxicity oral test. However, this negative effects were only observed in animals in test groups > 2000 mg/kg, thus the substance is not classified according to CLP.
Based on the available information, it is reasonable to assume that 100% of MMB-AC will gain systemic circulation by the oral route of administration. However, in the absence of experimental absorption data and in accordance with the ECHA Guidance R.8 (2012) a default value of 50% for oral absorption will be used in the derivation of DNELs.
Dermal:
Based on the physical/chemical properties, MMB-AC is likely to be absorbed after dermal application. According to the ECHA Guidance Chapter R.7c (2017), molecular weights of less than 500g/mol are capable of migration through the skin into systemic circulation. In addition, both water and lipid solubility influences the potential for dermal penetration. Based on the hydrolysis data for MMB-AC, the substance is regarded to be stable at pH 4 and thus penetration of the substance as such is expected.
The hypothesis for dermal absorption cannot be substantiated by toxicity studies since MMB-AC is not classified for dermal toxicity.
In the absence of experimental absorption data and in accordance with the ECHA Guidance R.8 (2012), a default value of 50% for dermal absorption will be used in the derivation of DNELs.
Inhalation:
MMB-AC is a liquid at room temperature with limited volatility. The vapour pressure of MMB-AC is 2.58 hPa at 25°C, which limits the likelihood of significant systemic exposure by inhalation of vapors. However, if MMB-AC is aerosolized, absorption across the respiratory epithelium would likely be rapid based on its partition coefficient and low molecular weight.
In the absence of experimental absorption data, a worst case absorption percentage of 100% has been taken into account for the inhalation route. - Details on distribution in tissues:
- The distribution of MMB-AC has not been characterized. Following oral exposure MMB-AC would enter hepatic portal circulation resulting in initial distribution to the liver. Given its size and water solubility, MMB-AC and/or its metabolites is expected to freely distribute systemically via the blood. Effects observed in the repeated dose toxicity study substantiate this hypothesis. In these study treatment-related decreases in RBC in males and females, decreases in Hb and Ht in females were noted in the 1000 mg/ kg groups. In addition, in the acute toxicity oral test, hunched posture, lethargy, decreased respiratory rate, increased salivation and ataxia was observed amongst treated rats, ptosis was seen in all rats treated with 2500 mg/kg and above, comatose-like conditions was seen amongst rats treated at 4000 and 5000 mg/kg and in the 4000 mg/kg test group increased lacrimation was observed in four animals. These observations provide evidence for an effect of the substance on the central nervous system, which is an indirect indication that the substance can cross the blood-brain-barrier.
No adverse effects where observed for reproduction and developmental toxicity.
Dermal absorption would result in general systemic exposure. The hypothesis for dermal absorption cannot be substantiated by toxicity studies since MMB-AC showed no adverse effects in the acute toxicity dermal test.
By inhalation, the distribution would also be expected to be more general as absorption by the lungs would result in distribution systemically via cardiac output. No experimental data are available to substantiate this hypothesis.
- Details on excretion:
- The polarity and water solubility of MMB-AC would facilitate its rapid excretion in urine. Any of the metabolic steps described above would further increase its polarity and thus enhance urinary excretion. Following of the possible Phase II reaction the molecular weight of the compound could increase to ~330 g/mol and therefore could be eliminated in faeces via bile (for rats, while a higher molecular weight is necessary in humans (~500 g/mol*)).
*Yang et al.; Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships; The AAPS Journal, Vol. 11, No. 3, 2009
Metabolite characterisation studies
- Details on metabolites:
- Once absorbed, MMB-AC is likely to be rapidly hydrolysed by esterases to the corresponding alcohols and carboxylic acid. It will be expected that MMB-AC will be hydrolysed by ester hydrolysis to 3-Methoxy-3-methyl-1-butanol (CAS 56539-66-3). This substance is registered according to REACH and the metabolism of MMB is described (theoretically) in the REACH registration dossier of the substance* . It is expected, that a substantial amount of MMB will undergo ether-bond cleavage to the 3-Methyl-1,3-butandiol (CAS 2568-33-4) and formaldehyde and formic acid. 3-Methyl-1,3-butandiol is fully water soluble and can be expected to be excreted fast. Glycoles are known to be consumed by oxidation to the aldehyde and further to the carboxylic acid. All metabolites can be expected to be excreted via urine or enter metabolic pathways to produce CO2.
Hydroxy and acid groups produced from Phase I metabolism could be subject to Phase II conjugate reactions to give glucuronide and sulphate conjugates.
*https://echa.europa.eu/de/registration-dossier/-/registered-dossier/10042 (ECHA, 2019)
Any other information on results incl. tables
The physical/chemical properties of MMB-AC are listed in the table below. These data show that MMB-AC is a small, polar, water soluble molecule.
MMB-AC |
|
Molecular formula |
C8H16O3 |
Molecular Weight |
160.21 |
Physical state |
Liquid at 20°C and 1013 hPA |
Melting/Freezing point (°C) |
< - 100 |
Boiling point (°C) |
187.3 at 1013 hPA |
Density (g/cm3) |
0.957 at 20°C |
Vapor pressure (Pa) |
258 at 25°C |
Water solubility (g/L) |
58.3 at 20°C |
Partition coefficient (log Kow) |
1.6 at 25°C |
Applicant's summary and conclusion
- Conclusions:
- MMB-AC can be assumed to be absorbed by the oral, dermal, and inhalation routes of exposure therefore systemic exposure is likely. However, in the absence of experimental data default absorption values are used in the derivation of DNELs, according to REACH guidance R.8.
MMB-AC is likely to be rapidly metabolized to hydroxy and acid metabolites which could then be conjugated.
MMB-AC is unlikely to bioaccumulate because of its polarity, extensive metabolism and rapid excretion.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.